EcoDrugPlus

Sodium/potassium-Transporting Atpase Subunit Alpha-1

Ensembl ID : ENSPNYG00000021807
Gene Symbol: LOC102214569
3 Cross references
198 Possible Orthologues:

Sodium/potassium-Transporting Atpase Subunit Alpha-1-Like

Ensembl ID : ENSPNYG00000021840
Gene Symbol: LOC102215134
3 Cross references
198 Possible Orthologues:

Sodium/potassium-Transporting Atpase Subunit Alpha-1-Like

Ensembl ID : ENSPNYG00000021866
Gene Symbol: LOC102215795
3 Cross references
169 Possible Orthologues:

Sodium/potassium-Transporting Atpase Subunit Alpha-1-Like

Ensembl ID : ENSPNYG00000021881
Gene Symbol: LOC102216091
3 Cross references
169 Possible Orthologues:

Sodium/potassium-Transporting Atpase Subunit Alpha-2-Like

Ensembl ID : ENSPNYG00000002116
Gene Symbol: LOC102205315
3 Cross references
205 Possible Orthologues:

Sodium/potassium-Transporting Atpase Subunit Beta-2-Like

Ensembl ID : ENSPNYG00000018647
Gene Symbol: LOC102204512
3 Cross references
203 Possible Orthologues:

Sodium/potassium-Transporting Atpase Subunit Beta-2-Like

Ensembl ID : ENSPNYG00000023775
Gene Symbol: LOC102214325
3 Cross references
197 Possible Orthologues:

Sodium/potassium-Transporting Atpase Subunit Beta-233-Like

Ensembl ID : ENSPNYG00000022156
Gene Symbol: LOC102197711
3 Cross references
220 Possible Orthologues:

Solute Carrier Family 18 Member A2

Ensembl ID : ENSPNYG00000003555
Gene Symbol: SLC18A2
3 Cross references
216 Possible Orthologues:

Solute Carrier Family 22 Member 6-Like

Ensembl ID : ENSPNYG00000013491
Gene Symbol: LOC102212639
3 Cross references
358 Possible Orthologues:

Solute Carrier Family 29 Member 1 (Augustine Blood Group)

Ensembl ID : ENSPNYG00000001623
Gene Symbol: SLC29A1
3 Cross references
209 Possible Orthologues:

Solute Carrier Family 29 Member 1 (Augustine Blood Group)

Ensembl ID : ENSPNYG00000017098
Gene Symbol: SLC29A1
3 Cross references
206 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).